½ÇÇè½Ç¿¡¼ È®ÀÎµÈ COVID-19¸¦ °¡Áø 366¸íÀÇ ÄÚȣƮ¸¦ »ç¿ëÇÏ¿© 2020³â 1¿ùºÎÅÍ 2020³â 2¿ù±îÁö ¾²ÃÓ¼º 47°³¼Ò¿¡¼ ¼öÁýÇÑ µ¥ÀÌÅ͸¦ »ç¿ëÇÏ¿© ¿¹Ãø ¸ðµ¨À» °³¹ßÇß´Ù. ÁÖ¿ä °á°ú´Â ÀÔ¿ø Áß ½É°¢ÇÑ COVID-19ÀÇ °³¹ßÀ̾ú´Ù. µ¥ÀÌÅÍ Å©±â¸¦ ÁÙÀÌ°í °ü·Ã ±â´ÉÀ» ¼±ÅÃÇϱâ À§ÇØ ÃÖ¼Ò Àý´ë ¼öÃà ¹× ¼±Åà ¿¬»êÀÚ(LASSO) ȸ±Í ¸ðµ¨À» »ç¿ëÇß´Ù. ´Ùº¯·® ·ÎÁö½ºÆ½ ȸ±Í ºÐ¼®À» Àû¿ëÇÏ¿© ¼±ÅÃÇÑ Çü»óÀ» ÅëÇÕÇÑ ¿¹Ãø ¸ðµ¨À» ±¸ÃàÇÏ¿´´Ù.
Á¦ 1Æí : Äڷγª-19ÀÇ Á¤ÀÇ
1. Äڷγª¹ÙÀÌ·¯½º°¨¿°Áõ-19(COVID-19) Á¤º¸ 7
2. Äڷγª¹ÙÀÌ·¯½º ºÐ·ù ¹× Ư¼º 9
3. Äڷγª ¹ÙÀÌ·¯½º ÀüÀÚÇö¹Ì°æ ÇüÅ 11
4. Äڷγª¹ÙÀÌ·¯½º ±¸Á¶ (Covid-19 Organization) 13
5. Äڷγª19: ȯ°æ¿¡ Áö¼ÓÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥±î? 19
6. Ä¡·á¹ý(Therapeutical Method) 22
Á¦ 2Æí : ¿¬±¸³í¹®
Development and validation a nomogram for predicting the risk of
severe COVID-19: A multi-center study in Sichuan, China
Methods 23
Introduction 24
Patients and methods 24
Demographical and risk variables 25
Results 28
Discussion 29
Conclusion 32
References 33